Virtual CRO seeks to help life sciences companies meet new federal guidelines for diversity, equity, and inclusion in clinical trials.
Curavit Clinical Research has announced its Inclusivity, Diversity, and Equity in Action (IDEA) toolkit. IDEA is a clinical trial planning and support service designed to help clinical trial sponsors navigate challenges in developing and executing diversity action plans, now required by law for most clinical trials in the United States. Curavit's IDEA toolkit delivers support across five key functional areas:
Two early adopters of Curavit's new service offering have leveraged planning templates to ensure that they were familiar with the underrepresented patient populations that would be important to include in the trial, to compile effective strategies to recruit diverse groups of patients for enrollment, and to identify potential sites and investigators already engaged with the desired patient populations.
Curavit Clinical Research Launches First Clinical Trial DEI Planning Toolkit. (2023, June 21). Cision PR Newswire.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.